DK2233483T3 - Indol- eller benzimidazol-derivater til modulering af IKB-kinase og mellemprodukter til fremstilling deraf - Google Patents

Indol- eller benzimidazol-derivater til modulering af IKB-kinase og mellemprodukter til fremstilling deraf

Info

Publication number
DK2233483T3
DK2233483T3 DK10163200.8T DK10163200T DK2233483T3 DK 2233483 T3 DK2233483 T3 DK 2233483T3 DK 10163200 T DK10163200 T DK 10163200T DK 2233483 T3 DK2233483 T3 DK 2233483T3
Authority
DK
Denmark
Prior art keywords
indole
intermediates
modulating
preparation
benzimidazole derivatives
Prior art date
Application number
DK10163200.8T
Other languages
English (en)
Inventor
Olaf Ritzeler
Gerhard Jaehne
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK2233483T3 publication Critical patent/DK2233483T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
DK10163200.8T 2002-08-17 2003-08-05 Indol- eller benzimidazol-derivater til modulering af IKB-kinase og mellemprodukter til fremstilling deraf DK2233483T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10237722A DE10237722A1 (de) 2002-08-17 2002-08-17 Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
EP03793685A EP1530568B1 (de) 2002-08-17 2003-08-05 INDOL-ODER BENZIMIDAZOLDERIVATE ZUR MODULATION DER IkB-KINASE

Publications (1)

Publication Number Publication Date
DK2233483T3 true DK2233483T3 (da) 2012-08-20

Family

ID=31968974

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10163200.8T DK2233483T3 (da) 2002-08-17 2003-08-05 Indol- eller benzimidazol-derivater til modulering af IKB-kinase og mellemprodukter til fremstilling deraf
DK03793685.3T DK1530568T3 (da) 2002-08-17 2003-08-05 Indol- eller benzimidazolderivater til modulering af ikb-kinasen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK03793685.3T DK1530568T3 (da) 2002-08-17 2003-08-05 Indol- eller benzimidazolderivater til modulering af ikb-kinasen

Country Status (43)

Country Link
US (2) US7285560B2 (da)
EP (2) EP2233483B1 (da)
JP (1) JP4504812B2 (da)
KR (1) KR101162046B1 (da)
CN (1) CN1314683C (da)
AR (1) AR040975A1 (da)
AT (2) ATE557018T1 (da)
AU (1) AU2003263196B2 (da)
BR (1) BR0313562A (da)
CA (1) CA2498559C (da)
CO (1) CO5690586A2 (da)
CR (1) CR7668A (da)
CY (2) CY1111692T1 (da)
DE (2) DE10237722A1 (da)
DK (2) DK2233483T3 (da)
EC (1) ECSP055612A (da)
ES (2) ES2358795T3 (da)
HK (1) HK1079509A1 (da)
HN (1) HN2003000249A (da)
HR (1) HRP20050042B1 (da)
IL (1) IL166785A0 (da)
JO (1) JO2764B1 (da)
MA (1) MA27382A1 (da)
ME (1) MEP60608A (da)
MX (1) MXPA05001314A (da)
MY (1) MY140074A (da)
NO (1) NO330981B1 (da)
NZ (1) NZ538296A (da)
OA (1) OA12908A (da)
PA (1) PA8580501A1 (da)
PE (1) PE20040893A1 (da)
PL (1) PL374229A1 (da)
PT (2) PT2233483E (da)
RS (1) RS51902B (da)
RU (1) RU2318820C2 (da)
SI (2) SI1530568T1 (da)
SV (1) SV2004001599A (da)
TN (1) TNSN05045A1 (da)
TW (1) TWI290552B (da)
UA (1) UA78591C2 (da)
UY (1) UY27941A1 (da)
WO (1) WO2004022553A1 (da)
ZA (1) ZA200500322B (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237723A1 (de) * 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
BRPI0511029A (pt) * 2004-05-12 2007-11-27 Aventis Pharma Inc ácido 2-{[2-(2-metil amino-pirimidin-4-il)-1h-indol-5-carbonil]-amino}-3-(feni l piridin-2-il-amino)-propiÈnico substancialmente puro como um inibidor da i capa b quinase
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
DE102004033406A1 (de) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
DOP2006000010A (es) * 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
WO2006076318A1 (en) * 2005-01-12 2006-07-20 Aventis Pharmaceuticals Inc. Monopotassium salt of an ikb kinase inhibitor
US20070142417A1 (en) * 2005-05-11 2007-06-21 Aventis Pharmaceuticals Inc Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor
DE102005025225A1 (de) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
CA2613068A1 (en) 2005-06-30 2007-01-11 Smithkline Beecham Corporation Indole carboxamides as ikk2 inhibitors
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) * 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
DK1910384T3 (da) * 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
US8088928B2 (en) * 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP2266561A3 (en) 2005-09-07 2011-05-18 Merck Serono S.A. IKK Inhibitors for the Treatment of Endometriosis
JP2009001495A (ja) * 2005-10-13 2009-01-08 Taisho Pharmaceutical Co Ltd ２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2011502984A (ja) * 2007-11-01 2011-01-27 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターとしてのアミド誘導体
US20110009381A1 (en) * 2007-11-08 2011-01-13 Sirtis Pharmaceuticals, Inc. Solubilized thiazolopyridines
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
EP2376502B1 (en) 2008-12-19 2015-06-17 GlaxoSmithKline LLC Thiazolopyridine sirtuin modulating compounds
WO2010099527A1 (en) * 2009-02-27 2010-09-02 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
EP3378854B1 (en) 2010-01-27 2022-12-21 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
NZ603802A (en) * 2010-04-27 2014-05-30 Hutchison Medipharma Ltd Pyrimidinyl indole compounds
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
MA34464B1 (fr) 2010-08-12 2013-08-01 Sanofi Sa Procede pour la preparation de formes enantiomeres de derives d'acide 2,3- diaminopropionique
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
JP5790440B2 (ja) 2010-12-01 2015-10-07 住友化学株式会社 ピリミジン化合物およびその有害生物防除用途
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
RS60190B1 (sr) 2011-07-27 2020-06-30 Astrazeneca Ab 2-(2,4,5-supstituisani-anilino) pirimidinski derivati kao egfr modulatori korisni za lečenje raka
EP2748147B1 (en) 2011-08-25 2017-08-02 St. Jude Children's Research Hospital Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinoline-4-carboxamides for antimalarial therapies
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MX351994B (es) * 2011-12-06 2017-11-06 Sanofi Sa Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico.
EA036521B1 (ru) * 2012-01-27 2020-11-19 Астразенека Аб Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
KR101493877B1 (ko) 2013-03-29 2015-02-16 농업회사법인 주식회사 생명의나무 스피나스테롤 당 유도체를 포함하는 골 질환 예방 또는 치료용 약학 조성물
EP2805705B1 (en) 2013-05-23 2016-11-09 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
EP2905282A1 (en) * 2014-02-05 2015-08-12 AXXAM S.p.A. Substituted thiazole or oxazole as P2X7 receptor antagonists
EP3164131B1 (en) 2014-07-03 2018-08-22 Sanofi 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide for use in the treatment of pain associated to osteoarthritis
CN116850181A (zh) 2015-01-06 2023-10-10 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
MX2017016530A (es) 2015-06-22 2018-03-12 Arena Pharm Inc Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto1) para ser utilizada en transtornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1).
EP3290416A1 (en) * 2016-08-31 2018-03-07 AXXAM S.p.A. Substituted n-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives and their use as p2x7 receptor antagonist
CN106588803A (zh) * 2016-11-16 2017-04-26 西南科技大学 一种制备5‑乙酰基异噁唑的新方法
CN108299302A (zh) * 2017-01-11 2018-07-20 西南科技大学 一种制备3-乙酰基吡唑的新方法
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
CN115052860B (zh) * 2020-01-30 2024-06-21 艾尼莫生物科技公司 胶原蛋白1翻译抑制剂和其使用方法
CN115974849B (zh) * 2022-12-28 2024-06-21 中国药科大学 一种吲哚氧乙酰胺类衍生物、包含其的药物组合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0664792B1 (en) 1992-10-14 2000-01-05 Merck & Co. Inc. Fibrinogen receptor antagonists
GB9225141D0 (en) 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
IT1275433B (it) * 1995-05-19 1997-08-07 Smithkline Beecham Farma Derivati di diarildiammine
EP1194425B1 (de) 1999-06-23 2005-08-10 Aventis Pharma Deutschland GmbH Substituierte benzimidazole
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
CA2436770A1 (en) 2001-02-01 2002-08-08 James R. Burke Methods of treating inflammatory and immune diseases using inhibitors of ikb kinase (ikk)
DE10237723A1 (de) * 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7462638B2 (en) * 2002-08-17 2008-12-09 Sanofi-Aventis Deutschland Gmbh Use of IκB-kinase inhibitors in pain therapy
US7046741B2 (en) * 2004-04-16 2006-05-16 Data Flow Technologies, Inc. Single and multiple sinewave modulation and demodulation techniques, apparatus, and communications systems

Also Published As

Publication number Publication date
ATE557018T1 (de) 2012-05-15
RS51902B (sr) 2012-02-29
HK1079509A1 (en) 2006-04-07
CY1112991T1 (el) 2016-04-13
SV2004001599A (es) 2004-02-26
HRP20050042A2 (en) 2006-03-31
SI1530568T1 (sl) 2011-05-31
RU2318820C2 (ru) 2008-03-10
US8778955B2 (en) 2014-07-15
EP2233483B1 (de) 2012-05-09
EP2233483A1 (de) 2010-09-29
HRP20050042B1 (hr) 2013-09-30
KR101162046B1 (ko) 2012-07-04
SI2233483T1 (sl) 2012-08-31
UY27941A1 (es) 2004-03-31
UA78591C2 (en) 2007-04-10
PL374229A1 (en) 2005-10-03
TW200418832A (en) 2004-10-01
EP1530568A1 (de) 2005-05-18
NZ538296A (en) 2007-03-30
PA8580501A1 (es) 2004-04-23
CA2498559C (en) 2012-01-24
AU2003263196A1 (en) 2004-03-29
KR20050058338A (ko) 2005-06-16
CY1111692T1 (el) 2015-10-07
CN1675196A (zh) 2005-09-28
BR0313562A (pt) 2006-06-13
AR040975A1 (es) 2005-04-27
PT1530568E (pt) 2011-02-23
RU2005107418A (ru) 2005-08-27
DK1530568T3 (da) 2011-04-18
CA2498559A1 (en) 2004-03-18
RS20050104A (en) 2007-06-04
CN1314683C (zh) 2007-05-09
DE10237722A1 (de) 2004-08-19
CO5690586A2 (es) 2006-10-31
MEP60608A (en) 2011-05-10
AU2003263196B2 (en) 2009-01-22
DE50313372D1 (de) 2011-02-10
JP4504812B2 (ja) 2010-07-14
NO330981B1 (no) 2011-08-29
NO20051337L (no) 2005-05-03
MY140074A (en) 2009-11-30
ATE493402T1 (de) 2011-01-15
US20050197353A1 (en) 2005-09-08
ECSP055612A (es) 2005-04-18
JO2764B1 (en) 2014-03-15
HN2003000249A (es) 2008-08-06
ES2387954T3 (es) 2012-10-04
PT2233483E (pt) 2012-07-20
MXPA05001314A (es) 2005-04-28
ES2358795T3 (es) 2011-05-13
PE20040893A1 (es) 2004-12-21
US7285560B2 (en) 2007-10-23
IL166785A0 (en) 2006-01-15
TNSN05045A1 (en) 2007-05-14
OA12908A (en) 2006-10-13
TWI290552B (en) 2007-12-01
JP2005539054A (ja) 2005-12-22
US20070244139A1 (en) 2007-10-18
ZA200500322B (en) 2006-07-26
MA27382A1 (fr) 2005-06-01
CR7668A (es) 2009-03-11
WO2004022553A1 (de) 2004-03-18
EP1530568B1 (de) 2010-12-29

Similar Documents

Publication Publication Date Title
DK2233483T3 (da) Indol- eller benzimidazol-derivater til modulering af IKB-kinase og mellemprodukter til fremstilling deraf
DK1656370T3 (da) Heterocykliske biarylforbindelser og fremgangsmåder til fremstilling og anvendelse af samme
DE60336314D1 (de) Substituierte indole
DK1922309T3 (da) N-phenyl-2-pyrimidin-aminderivater og fremgangsmåde til fremstillingen deraf
DK1465615T3 (da) Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
DK1677735T3 (da) Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
DK1504126T3 (da) Fremgangsmåde til regulering af genekspression
NO20051451D0 (no) Pyrimidinderivater og deres anvendelse som CB2 modulatorer
NO20053356D0 (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
DK1732892T3 (da) Tetrahydrocarbazoler og derivater
DK1879573T3 (da) Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
DK1513832T3 (da) Indol, azaindol og relaterede heterocykliske 4-alkenylpiperidinamider
ATE455767T1 (de) Heterozyklische vegfr-2 kinase inhibitoren
NO20054095D0 (no) Pyridyloksymetyl og benzioksazolazabicyklisk derivater
NO20041008L (no) Karbazolderivater og anvendelse derav som NPY5 reseptor antagonister
NO20035562L (no) System og fremgangsmate for forenklet initiering av konferanser
ATE292115T1 (de) Indolderivate als cox-ii-inhibitoren
NO20043580L (no) Quinazolinonderivater og deres bruk som CB agonister
DK1578727T3 (da) Tetrahydroquinolin-derivater og deres anvendelse som FSH-receptor-modulatorer
DK1768691T3 (da) Aequorinholdige præparater og fremgangsmåder til anvendelse af samme
NO20034434D0 (no) Indolinoner substituert i 6-stilling og deres anvendelse som kinase-inhibitorer
NO20054141D0 (no) Substituerte 2-(diaza-bicykloalkyl)pyrimidonderivater
DK1469719T3 (da) System og fremgangsmåde til væsk af æg
DK1802571T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af derivater af N-(1-benzhydryl-azetidin-3-yl)- N-phenyl-methylsulfonamid
IS8002A (is) Setið indólín og indól afleiður